UNSPSC 51434302: Diazoxide

This classification denotes a vasodilating agent with the molecular formula C8H7ClN2O2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier O5CB12L4FN, chemically known as 7-chloro-3-methyl-2h-1,2,4-benzothiadiazine 1,1-dioxide but generally known as diazoxide, which bears US NIH Compound Identifier 3019. European Medicines Agency schedules Diazoxide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07071MIG.

UNSPSC 51434302 Diazoxide is a Commodity code representing pharmaceutical supplies, specifically vasodilator medications used in emergency and acute-care settings. State and local governments procure diazoxide and related advanced life support medications through municipal fire and rescue departments, state health agencies, and multistate cooperative purchasing alliances. The solicitations under this code reflect acquisition of specific injectable medications with stringent expiration, storage, and delivery requirements, often bundled with broader advanced life support medication procurement. Issuing bodies include municipal purchasing departments (fire rescue services), state health and human services commissions, and cooperative purchasing entities serving multiple jurisdictions.

Recent activity centers in Florida and Minnesota, with Texas health agencies conducting exploratory market research. The City of Tampa's Purchasing Department issued an IFB (Bid No. 26-P-00188) in April 2026 for Advanced Life Support Medications for Tampa Fire Rescue, due April 8, 2026, with an estimated contract value of $40,000 and a one-year term with two optional renewals; the solicitation carried a 5 percent Small Local Business Enterprise bid discount. The Minnesota Department of Administration's Office of State Procurement, administering the MMCAP cooperative purchasing vehicle, issued an RFP (S1070000015802) due March 26, 2026 for generic multi-source pharmaceuticals and OTC products distributed across state and local facilities in Minnesota and Oregon, with contract effectiveness July 1, 2026 and a two-year term. The Texas Health and Human Services Commission issued an exploratory RFI (HHS0017013) in April 2026 regarding direct-to-manufacturer pharmacy programs, signaling preliminary interest in alternative supply models for prescription medications beyond traditional pharmacy benefit manager channels.